Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): A randomised controlled trial

The Lancet Oncology

Volumn 14, Issue 3, 2013, Pages 199-209

  Vora, Ajay ^a   Goulden, Nick ^b   Wade, Rachel ^c   Mitchell, Chris ^d   Hancock, Jeremy ^e   Hough, Rachael ^f   Rowntree, Clare ^g   Richards, Sue ^c  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e NORTH BRISTOL NHS TRUST   (United Kingdom)

^f UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AVASCULAR NECROSIS; BONE MARROW BLAST COUNT; BRAIN DISEASE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM THROMBOSIS; CHILD; COLITIS; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE; DRUG DOSE DELAYED INTENSIFICATION; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG PULSE THERAPY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOLOGICAL PARAMETERS; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; INDUCTION CHEMOTHERAPY; INFANT; INFECTION; INTENTION TO TREAT ANALYSIS; IRELAND; LEUKOCYTE COUNT; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYCOSIS; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK ASSESSMENT; SCHOOL CHILD; SEIZURE; STANDARD; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; IRELAND; MALE; METHOTREXATE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 84875273960     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70600-9     Document Type: Article

References (40)

1. Mitchell C, Payne J, Wade R, et al. The impact of risk stratification by early bone-marrow response in childhood lymphoblastic leukaemia: results from the United Kingdom Medical Research Council trial ALL97 and ALL97/99. Br J Haematol 2009, 146:424-436.
2. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007, 109:896-904.
3. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008, 111:4477-4489.
4. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004, 104:2690-2696.
5. Cavé H, van der Werff ten Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. N Engl J Med 1998, 339:591-598. for the European Organisation for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group.
6. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
7. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
8. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009, 360:2730-2741.
9. Yamaji K, Okamoto T, Yokota S, et al. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 2010, 55:1287-1295.
10. Szczepanski T, van der Velden VH, van Dongen JJ Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol 2003, 16:561-582.
11. Biondi A, Schrappe M, Di Lorenzo P, et al. Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL): the EsPhALL Study. Blood 2011, 118:873.
12. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukaemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
13. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010, 24:521-535.
14. Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008, 22:771-782.
15. Altman DG Practical statistics for medical research 1991, Chapman and Hall, London.
16. Vora A, Wade R, Mitchell CD, Goulden N, Richards S Improved outcome for children and young adults with T-cell acute lymphoblastic leukaemia (ALL): results of the United Kingdom Medical Research Council (MRC) Trial UKALL 2003. Blood 2008, 112:908.
17. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000, 95:2770-2775.
18. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007, 297:1207-1215.
19. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia 2010, 24:371-382.
20. Schrappe M, Nachman J, Hunger S, et al. Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000). Leukemia 2010, 24:253-254.
21. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003, 101:3809-3817.
22. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005, 129:734-745.
23. Schrappe M, Zimmermann M, Moricke A, et al. Dexamethasone in induction can eliminate one third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomized trial in 3655 patients (trial AIEOP-BFM ALL 2000). Blood 2008, 112:7.
24. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006, 91:24-31.
25. Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006, 46:18-25.
26. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002, 99:1986-1994.
27. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000, 110:379-384.
28. Hurwitz CA, Silverman LB, Schorin MA, et al. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 2000, 88:1964-1969.
29. McNeer JL, Nachman JB The optimal use of steroids in paediatric acute lymphoblastic leukaemia: no easy answers. Br J Haematol 2010, 149:638-652.
30. Moricke A, Zimmermann M, Schrauder A, et al. No influence on the incidence of osteonecroses when dexamethasone replaces prednisone during induction treatment for childhood ALL: results of trial ALL-BFM 2000. Blood 2008, 112:899.
31. de Vries MA, van Litsenburg RR, Huisman J, et al. Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. Health Qual Life Outcomes 2008, 6:103.
32. Kadan-Lottick NS, Brouwers P, Breiger D, et al. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009, 114:1746-1752.
33. Zeidan A, Wang ES, Wetzler M Pegasparaginase: where do we stand?. Expert Opin Biol Ther 2009, 9:111-119.
34. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011, 118:243-251.
35. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008, 111:2548-2555.
36. Lee-Sherick AB, Linger RM, Gore L, et al. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 2010, 151:295-311.
37. Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010, 150:352-358.
38. Cario G, Schrauder A, Moericke A, et al. Early diagnosis and molecular-based treatment of very highly resistant acute lymphoblastic leukemia in childhood. Blood 2008, 112:754.
39. Harrison CJ, Haas O, Harbott J, et al. Detection of prognostically relevant genetic abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: recommendations from the Biology and Diagnosis Committee of the International Berlin-Frankfurt-Munster study group. Br J Haematol 2010, 151:132-142.
40. Izraeli S Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?. Br J Haematol 2010, 151:119-131.